Zoetis: Buy Rating Affirmed Amid Strong Companion Animal Growth and Optimistic Outlook

William Blair analyst Brandon Vazquez has maintained their bullish stance on ZTS stock, giving a Buy rating on April 28.

Brandon Vazquez has given his Buy rating due to a combination of factors including Zoetis’s strong performance in key segments and an optimistic outlook. The company has shown impressive growth in its companion animal segment, which is crucial for investor sentiment, despite some challenges in the livestock area.
Additionally, Zoetis has increased its full-year sales and EPS guidance, benefiting from easing foreign exchange headwinds, which further supports the positive rating. The company’s key products in the parasiticides and dermatology categories, which make up a significant portion of its revenue, have exceeded expectations, reinforcing the potential for durable growth.

In another report released on April 28, HSBC also maintained a Buy rating on the stock with a $180.00 price target.

Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ZTS in relation to earlier this year.